Advanced Bioscience Laboratories, Inc.
Advanced Bioscience Laboratories, Inc. (ABL), doing business as Advanced Bioscience Laboratories Inc., is a leading contract research and manufacturing organization specializing in the development of gene therapies, vaccines, oncolytics, and immunotherapies. As a foreign-owned, for-profit manufacturer of goods, ABL provides a wide range of preclinical and clinical development services to support infectious disease research and product development initiatives for government agencies, academic institutions, and industry clients. The company's expertise spans biologics manufacturing, testing, storage, shipping, and quality assurance services. ABL has been awarded numerous federal contracts and grants, particularly from the National Institutes of Health (NIH) and Department of Health and Human Services (HHS), to advance the development of medical countermeasures for various infectious diseases and other health conditions.
Through its federal contract awards, ABL has provided a diverse array of goods and services to support preclinical and clinical development programs. These include cGMP manufacturing of vaccines and biologics, process development, analytical testing, stability studies, and project management for infectious disease countermeasures such as HIV, influenza, and other vaccines and therapeutics. ABL has performed work for multiple NIH institutes, including the National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), and National Institute of Neurological Disorders and Stroke (NINDS). The company has contributed to various programs, including HIV microbicides and biomedical prevention, pediatric drug formulation development, and cancer prevention initiatives. Notable projects include the manufacture of glycopeptide immunogen nanoparticle vaccines, development of bitter taste receptor blockers for pediatric medicines, and production of vaccines targeting frame-shift mutations in tumors. ABL's contracts typically do not have set-aside designations, reflecting its status as a large business in the federal contracting landscape.
ABL's involvement in federal grant programs has primarily been as a subcontractor to academic institutions. The company has supported grants focused on vaccine development and immunology studies. For instance, ABL has worked on a project to develop MecVax, a cross-protective subunit vaccine for enterotoxigenic E. coli (ETEC), in collaboration with the University of Illinois. Another significant grant-funded project involved toxicology studies and assay verification for a gonococcal peptide vaccine (TMCP2) in partnership with the University of Massachusetts Medical School. In these projects, ABL's role typically includes conducting toxicology studies, verifying immunological assays such as ELISAs and bactericidal assays, and providing technical expertise in vaccine development and testing.
ABL holds several Indefinite Delivery Vehicles (IDVs) with federal agencies, demonstrating its broad capabilities in biopharmaceutical research and development. A notable IDV is with NIAID for the Diagnostics Pre-Clinical Services Program, valued at $24 million, which supports in vitro diagnostic development. Another significant IDV is with NINDS for Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders, with a ceiling of $149.2 million. ABL also holds an IDV with NIAID for Resources to Advance Pediatrics and HIV Prevention Science, valued at $98.9 million, covering a range of preclinical development support services. Additionally, the company has an IDV with NCI for the PREVENT Cancer Preclinical Drug Development Program, focused on cGMP production of vaccines and biologicals for cancer prevention. These IDVs collectively demonstrate ABL's comprehensive capabilities in supporting the development of vaccines, therapeutics, and diagnostics across multiple disease areas and federal health agencies.
MK4QC9EKZXG8 541714
Not listed 9800 Medical Center Dr, Rockville, MD 20850, USA
10/5/06 10/31/25 Bioqual, Inc.
Bioqual, Inc. is a fully accredited company that provides state-of-the-art facilities and experienced research scientists, veterinarians, and animal care personnel to support biomedical research. Through federal contracts, the company serves as a prime contractor conducting animal studies, providing lab analysis services, and housing and caring for research animals. As a subcontractor, Bioqual provides housing, care support, and maintenance of nonhuman primates.
Bioqual has received prime contract awards from the National Institutes of Health to conduct vaccine and therapeutic studies related to viruses, provide lab analysis for animal studies, and acquire services for rat and mice treatment studies. Awards have been made under purchase orders and also through task orders issued under indefinite-delivery/indefinite-quantity contracts like the Simian Vaccine Evaluation Units vehicle held by the National Institute of Allergy and Infectious Diseases. Additionally, Bioqual has provided animal housing services as a prime contractor to the Uniformed Services University of the Health Sciences.
As a subcontractor supporting grant awards, Bioqual has provided nonhuman primate procurement, housing, care, dosing, and tissue/biosample collection services. These awards were made under grants focused on HIV cure research, immune system studies, and testing of radiation recovery compounds. Prime grantees have included the University of Maryland Baltimore, Temple University, and the Henry M. Jackson Foundation.
Bioqual holds two indefinite-delivery contracts supporting federal research programs. One is the Simian Vaccine Evaluation Units vehicle allowing for task orders related to primate vaccine studies, care, and housing over a seven year period from the National Institute of Allergy and Infectious Diseases. The other is the Comprehensive and Rapid Response contract providing flexible acquisition of research support services like clinical trials and manufacturing to aid infectious disease research at the National Institute of Allergy and Infectious Diseases.
CK9LGQ7EBNN8 541715
Not listed 9600 Medical Center Dr #101, Rockville, MD 20850, USA
6/8/99 10/3/25 The Administrators Of Tulane Educational Fund
The Administrators Of The Tulane Educational Fund, doing business as Tulane University, is a private university located in New Orleans, Louisiana. According to its website, Tulane University is a comprehensive research university that strives to improve the lives of others in its community and globally. Through federal contract awards, The Administrators Of The Tulane Educational Fund has provided a range of goods and services, including research and development, professional services, and products to support federal agency missions.
As a prime contractor, The Administrators Of The Tulane Educational Fund has provided educational services, training programs, medical research, and technical expertise to agencies like the Department of Defense, Department of Health and Human Services, Department of Homeland Security, and National Aeronautics and Space Administration. For example, it received a $755,807 firm fixed price delivery order from the Department of the Navy Bureau of Naval Personnel to provide tuition and fees for Navy personnel. It also conducted medical research for the National Institutes of Health focused on disease areas like HIV, tuberculosis, and Alzheimer's disease. As a subcontractor, The Administrators Of The Tulane Educational Fund has supported partners on clinical trials, data analytics, disaster planning, and other research initiatives under contract vehicles from diverse federal entities.
Through federal grants, The Administrators Of The Tulane Educational Fund has received funding to deliver goods and services aligned with program goals around improving public health, advancing science and technology innovation, furthering education and workforce development, and more. As a prime grantee, it has received awards from agencies like the National Science Foundation, National Institutes of Health, Department of Education, and Department of Agriculture to support numerous research projects, strengthen institutional research infrastructure, provide STEM education and training programs, and assist vulnerable populations. As a subrecipient under other universities' grants, it has contributed expertise on initiatives covering topics ranging from maternal health to environmental justice.
The Administrators Of The Tulane Educational Fund holds an Indefinite Delivery Contract under the National Institutes of Health's Resources to Advance Pediatrics and HIV Prevention Science master contract vehicle. This multiple award contract covers preclinical development support services like animal model studies, product manufacturing, and scientific and quality services to facilitate future procurements around pediatric and HIV prevention science research priorities. The Administrators Of The Tulane Educational Fund received a $21,632 delivery order under this contract to support the master contract's goals.
XNY5ULPU8EN6 611310
Not listed Gibson Hall, 6823 St Charles Ave, New Orleans, LA 70118, USA
8/24/01 11/12/25